¹®¿ëÈ
Ç÷¾×Á¾¾ç³»°úÀå
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : À¯¹æ¾Ï, ºÎÀξÏ, Àü¸³¼±¾Ï
Á÷
ˤ
: ±³¼ö(Ç÷¾×Á¾¾ç³»°úÀå)
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
28
ÇØ¿Ü
Pandey K, An HJ, Kim SK, Lee SA, Kim S, Lim SM, Kim GM, Sohn J, Moon YW. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. Int J Cancer. Epub 2018
27
ÇØ¿Ü
Lim SM, An HJ, Park HS, Kwon HJ, Y Kim E, Hur J, Moon YW. Organizing pneumonia resembling disease progression in a non-small-cell lung cancer patient. Medicine (Baltimore) 97:e11646; 2018
26
ÇØ¿Ü
Hong SR, Hur J, Moon YW, et al.. Predictive factors for treatment response using dual-energy computed tomography in patients with advanced lung adenocarcinoma. Eur J Radiol 101; 118-123; 2018
25
ÇØ¿Ü
Park KS, Moon YW, Raffeldd M, et al.. High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer. Lung Cancer 116; 38-45; 2018
24
ÇØ¿Ü
Moon YW*, An H-J*, Koo JS, et al.. CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator. (*Both equally contributed). Oncotarget 9: 2622-30; 2017
23
ÇØ¿Ü
Rao G, Pierobon M, Kim IK, Hsu WH, Deng J, Moon YW, Petricoin EF, Zhang YW, Wang Y, Giaccone G. Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. Sci Rep 7:7066; 2017
22
ÇØ¿Ü
Lim SM, Park HS, Kim S, Kim S, Ali SM, Greenbowe JR, Yang IS, Kwon NJ, Lee JL, Ryu MH, Ahn JH, Lee J, Lee MG, Kim HS, Kim H, Kim HR, Moon YW, et al..Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Oncotarget 7: 10547-56; 2016
21
ÇØ¿Ü
Cho A, Hur J, Moon YW, et al.. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer. BMC Cancer 16: 224, 2016
20
ÇØ¿Ü
Park HS, Lim SM, Kim S, Kim S, Kim HR, Kwack K, Lee MG, Kim JH, Moon YW. Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution. Plos One 11: e0154133, 2016
19
ÇØ¿Ü
Heo SJ, Jung I, Lee CK, Kim JH, Lim SM, Moon YW, et al..A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.Cancer Chemother Pharmacol 77:539-548, 2016
1
2
3
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729